Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Nissay Asset Management Corp Japan ADV


Share on StockTwits

Nissay Asset Management Corp Japan ADV raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 120,385 shares of the company’s stock after acquiring an additional 3,292 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Teva Pharmaceutical Industries were worth $1,162,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TEVA. First Allied Advisory Services Inc. lifted its stake in Teva Pharmaceutical Industries by 52.6% during the third quarter. First Allied Advisory Services Inc. now owns 36,179 shares of the company’s stock valued at $326,000 after buying an additional 12,467 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $530,000. Bellecapital International Ltd. lifted its stake in Teva Pharmaceutical Industries by 63.1% during the fourth quarter. Bellecapital International Ltd. now owns 26,100 shares of the company’s stock valued at $252,000 after buying an additional 10,100 shares in the last quarter. California State Teachers Retirement System lifted its stake in Teva Pharmaceutical Industries by 0.8% during the third quarter. California State Teachers Retirement System now owns 1,296,404 shares of the company’s stock valued at $11,681,000 after buying an additional 9,783 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its stake in Teva Pharmaceutical Industries by 27.2% during the third quarter. Great West Life Assurance Co. Can now owns 524,407 shares of the company’s stock valued at $4,917,000 after buying an additional 111,997 shares in the last quarter. 51.20% of the stock is owned by institutional investors.

NYSE:TEVA opened at $10.84 on Tuesday. The stock’s 50 day moving average price is $11.71 and its 200 day moving average price is $10.17. Teva Pharmaceutical Industries Limited has a 52 week low of $6.25 and a 52 week high of $13.56. The company has a market capitalization of $11.84 billion, a P/E ratio of -2.95, a P/E/G ratio of 0.87 and a beta of 1.49. The company has a debt-to-equity ratio of 2.22, a quick ratio of 0.63 and a current ratio of 1.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, February 10th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. The firm had revenue of $4.45 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The firm’s revenue was down .3% on a year-over-year basis. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.42 earnings per share for the current fiscal year.

TEVA has been the subject of a number of research analyst reports. Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, November 24th. They issued a “market perform” rating for the company. BMO Capital Markets reduced their price target on shares of Teva Pharmaceutical Industries from $13.00 to $11.00 and set a “market perform” rating for the company in a research report on Friday, November 6th. Finally, Raymond James reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, December 28th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average price target of $11.48.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: What is a Fibonacci Channel?

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.